Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest PharmAthene Inc. Stories

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-11 16:20:56

ANNAPOLIS, Md., March 11, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the year ended December 31, 2013. "We remain focused on advancing our core biodefense programs, including addressing the SparVax(®) clinical hold which is our top priority," said Eric I. Richman, President and Chief Executive Officer. "We have a clear path...

2014-03-10 12:21:12

ANNAPOLIS, Md., March 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014. PharmAthene management will be hosting a conference call to discuss the Company's year-end 2013 financial and operational results. The call is scheduled to begin at 4:30 p.m....

2013-12-16 08:20:44

ANNAPOLIS, Md., Dec. 16, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax(®) rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The...

2013-12-02 08:21:32

ANNAPOLIS, Md., Dec. 2, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with consent from Theraclone. The agreement provided for the merger of a wholly-owned subsidiary of PharmAthene into Theraclone in an all-stock, merger-of-equals transaction. Accordingly, PharmAthene has cancelled the Special Meeting of Stockholders scheduled for December 3, 2013 and will pay Theraclone a $1...

2013-11-11 12:20:25

ANNAPOLIS, Md., Nov. 11, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today announced that new data from the Company's next-generation SparVax(®) recombinant protective antigen (rPA) anthrax vaccine program were published in the November issue of the American Society for Microbiology peer-reviewed journal Clinical and Vaccine Immunology. The article entitled, "Increasing the Potency...

2013-11-07 16:31:59

ANNAPOLIS, Md., Nov. 7, 2013 /PRNewswire/ -- Recent Highlights -- On track to commence SparVax(®) Phase 2 clinical trial -- Presented new SparVax(®) anthrax vaccine data at the 2013 Bacillus-ACT International Conference and the 53(rd) Annual Interscience Conference on Antimicrobial Agents and Chemotherapy -- Advanced proposed merger with Theraclone Sciences; filed amended Form S-4 registration statement and set date for special stockholders meeting...

2013-09-13 08:23:50

ANNAPOLIS, Md., Sept. 13, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax(® )next-generation anthrax vaccine program were presented at the 53(rd) Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax(®) provides dose-dependent protection against lethal anthrax infection. Dr. Sherry Crowe, Director, Immunology...

2013-09-09 08:27:56

ANNAPOLIS, Md., Sept. 9, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company. Under the terms of the merger...